Characterization and classification of external Quality Assessment Schemes (EQA) according to objectives such as evaluation of method and participant bias and standard deviation by Libeer, J.C. et al.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/23494
 
 
 
Please be advised that this information was generated on 2018-07-07 and may be subject to
change.
Eiir J Clin Chem Clin Biochem 1996; 34:665-678  ©  1996 by Walter de Gruyter ■ Berlin • New York
Classification of External Quality Assessment
Schemes (EQA) According to Objectives 
of Method and Participant Bias and Stai
Discussion paper from the members of the External Quality Assessment (EQA) Working Group A1)
on analytical goals in laboratory medicine
Jean Claude Liheer\  Henk Baadenhaijsen2, Callutn G. Fraser", Per Hylloft Petersen*, Carmen Ricos5, 
Dietmar Stockl6 and Linda Thienpont1
1 Instituut voor Hygiene en Epidemiologie, Klinische Biologie, Brussels, Belgium
2 Academisch Ziekenhuis Sint Radboud, Centraal Klinisch Chemisch Laboratorium, Nijmegen, The Netherlands
3 Ninewells Hospital and Medical School, Directorate of Biochemical Medicine, Dundee, Scotland, U. K.
4 Odense Universitetshospital, Klinisk Kemisk Afdeling (Centrallaboratoriet), Odense, Denmark
5 Hospital General Universitario Vail d’Hebron, Servicio de Bioquímica, Po Vail d’Hebron, Barcelona, Spain
6 Institut für Standardisierung und Dokumentation im medizinischen Laboratorium e. V. (INSTAND e. V«), 
Düsseldorf, Germany
7 Universiteit Gent, Faculteit Farmaceutische Wetenschappen, Laboratorium voor Analytische Chemie2), Gent, 
Belgium
Summary: Within the scope of this paper, the Working Group has attempted to place external quality assessment 
(EQA) within the whole context of quality management in laboratory medicine. First, the objectives of EQA 
schemes arc defined and current EQA schemes evaluated. In most schemes, the objectives are not defined a priori 
and do not allow the definition of the origin of unacceptable individual results from participants.
There is an ongoing trend for making traditional EQA schemes more interesting for the participants. Analysis of 
the factors involved in analytical quality allow the definition of the essential analytical tasks of educational EQA 
schemes. Beside these quality control tasks, educational EQA also includes quality assurance elements.
EQA today has not only an important role to play in the assessment of each participant’s performance but also in 
the assessment of the method. Efficiency of the schemes and educational impact can be improved by appropriate 
scheme designs according to objectives. After this theoretical approach, some practical examples of problem related 
EQA designs are given.
Introduction
»
Clinical laboratories have a long tradition of organisa­
tion and participation in external quality assessment 
(EQA) schemes. The first results in EQA schemes were 
reported by Belk Sl Sunderman (1) in 1947.
According to the ISO defmtion, external quality assess­
ment refers to a system of objectively checking labora­
tory results by means of an external agency, including 
comparison of a laboratory’s result at intervals with 
those of other laboratories, the main objective being the
') The Working Group is one o f four ad hoc groups meeting under 
the auspices o f the European external quality assessment (EQA) 
organizers group. The Working Groups were initiated by Adam 
UIda 11 following a meeting of EQA organizers and interested in­
dividuals in Cracow, Poland, in 1991 at Eurolab’ 91.
") Where D ietm ar Stockl presently is affiliated.
establishment of trueness (2). This definition is rather 
static and does not include any educational aspect. 
Moreover, only participant assessment is considered, 
while method assessment is also an essential element 
of EQA.
Instead of external quality assessment, the term “profi­
ciency testing ” is also used for the same definition de- 
scription (3). Proficiency testing is used rather in the 
scope of laboratory accreditation, allowing reimburse­
ment based on results obtained in such schemes. In prac­
tice, the difference between proficiency testing and EQA 
is not always clear.
Recently, some organizers of EQA schemes have taken 
a broader view of the objectives of “traditional” EQA 
schemes (4, 5) and consider it an obligation to develop 
educational programmes that actively support quality 
improvements according to the needs of the laboratories.
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In these schemes, the emphasis changes from assessing 
the quality of analytical work to assuring quality by ex­
ternal guidance. Olafsdottir et al. (5) used the term: 
"EQAssur” as the most appropriate for such schemes. 
In this paper, we use the term “educational” EQA 
schemes. We could define educational EQA as problem 
related external quality assessment, allowing the partici­
pants to define the origin of problems for aberrant results 
and to find the appropriate remedial procedure.
Within the scope of this paper, the Working Group has 
attempted
(i) to place EQA within the whole context of quality 
management in laboratory medicine,
(ii) to define the objectives of EQA schemes,
(iii) to evaluate current EQA schemes,
(iv) to define the essential tasks of educational EQA 
schemes and
(v) to describe the design of educational EQA schemes 
according to the objectives.
Finally, some examples of problem related EQA designs 
are given, demonstrating the benefits of this approach, 
independent of the distinction made between EQA and 
proficiency testing. The Working Group restricted itself 
only to problems related to analytical quality. Conse­
quently, areas such as preanalytical variation, test inter­
pretation and organisational structure of a laboratory are 
not dealt with.
View of the Working Group
Si tua t ion  o f  EQA wi th in  a total  qual i ty  
m a n a g e m e n t  concep t
in the NORDKEM protein project publications, Hyltoft 
Petersen et al. (6) described in detail a model for analyt­
ical quality achievement (fig. 1). According to this 
model, at least three main elements are identified as the 
basis factors for analytical quality. These are
(i) analytical quality specifications,
(ii) analytical quality creation and
(iii) analytical quality control
Within the model, EQA and internal quality control 
(IQC) are the two basic features of analytical quality
Fig. 1 Model for analytical quality illustrating the three basic 
elements as proposed by H yltoft Petersen  et ai. (6).
control, each with a proper design and proper control 
materials.
In order to evaluate analytical quality, knowledge about 
the required performance of the analytical procedure is 
needed. That means that the desired ana ly t i ca l  q u a l ­
ity spec i f i ca t ions  have to be defined before any con­
trol procedure can be applied.
Analyt ical  qual i ty  spec i f i ca t ions
For internal quality control, analytical quality specifica­
tions are based on more or less complicated models with 
direct transformations of the more general goal to opera­
tive values for analytical bias and analytical imprecision. 
Both terms define the specifications for total error.
The quality specifications for an EQA result are given 
in terms of location and dispersion. Location is defined 
by the target setting, which can be method dependent or 
method independent. Depending on the scheme design, 
dispersion includes random errors and the laboratoiy 
component o f bias or also inherent bias o f the measure­
ment procedure. For the definition of these error con­
cepts, we refer to Dybkaer (7), who defines laboratory 
bias as the sum of the bias of the measurement pro­
cedure and the laboratoiy component of bias.
Our Working Group described in another publication (8) 
to pros and the cons of different quality specifications 
and proposed desirable routine analytical goals for quan­
tities assayed in serum. In our opinion, the biological 
model is the most appropriate for EQA schemes, since 
this model is the most objective general approach. In 
some cases, e. g., therapeutic drug monitoring, phenyl­
ketonuria and thyroid stimulating hormone in neonatal 
screening tests, cholesterol and HbAic, acceptability 
limits for EQA results can be based on clinical concepts 
as, in these cases, the clinical use of these tests is well 
defined. The clinical concept relates directly to the clin­
ical use of laboratory data, whereby, it is the most rele­
vant approach to evaluation of analytical quality specifi­
cations. For most other situations, the laboratoiy does 
not know the exact clinical context in which the test 
result is asked; hence our proposal is to base acceptabil­
ity limits, used in EQA schemes, on the biological 
model as a general approach, based on a general back­
ground of within- and between-subject biological varia­
tions without specifying the clinical situation.
The other analytical quality specifications, based on 
state of the art, on reference values or on expert opinions 
are discussed in the above mentioned paper from the 
Working Group. In figure 2 , this extended model on ana­
lytical quality specifications is visualized.
Creat ion o f  qual i ty
Creation of quality is, on the one hand, the responsibility 
of the diagnostic and equipment manufacturers (creation
Libeer et al: Characterization and classification of external quality assessment schemes 667
of method quality) and, on the other hand, the re sp on si- ting of calibrators can be adjusted in order to compen-
bility of the individual laboratory (creation of laboratory sate for non-commutability of their matrix and to guar-
quality). The quality demanded by the coherent set of antee trueness of patient sample measurements. This
desirable performance standards must be created, taking work must be performed by industry itself or in collabo-
a number of factors into account. Lowering of im- ration with reference laboratories. A proposal for a
precision can be achieved by use of better instrumenta- European Network of Reference Laboratories, with suf-
tion and by the application of the techniques of quality ficient quality guarantees at the disposal o f industry, has
assurance within laboratories. In contrast, improvement been elaborated within Workgroup B (13). When refer-
in bias can be achieved only by better standardisation ence methods are not available, international reference
through international reference preparations and calibra- preparations should be used for target value assignment,
tors with values traceable through the hierarchy of meth- As an example we can mention here the BCR CRM for
ods and materials and by use of more specific methods enzymes (14-16).
(9). This fact is of particular importance today, because 
bias is the major challenge for current method develop­
ment (10). The European draft directive on in vitro diag­
nostics ( 1 1 ) also requires that standards and calibrators 
should be traceable to reference materials of a higher or­
der.
Creation o f laboratory quality is associated with labora­
tory organization (adequate space, sufficient well trained 
staff, solid financial basis, efficient maintenance, etc.), 
adequate test-kit and instrument selection, and correct 
implementation of test-kits in combination with the re­
commended calibrator(s) and measurement instruments
Creation o f method quality is mainly associated with available in the laboratory. All these aspects can be sum-
thorough pre-market method validation. Each method marized as “performance of procedures”. Creation of
should exhibit good sensitivity, specificity, precision, ro- laboratory quality as a function o f the desired quality
bustness and traceability. From all these characteristics, specifications requires that the laboratory applies con-
traceability to trueness is the most critical today. For a stant working procedures and working instructions; this
majority of clinical chemistry quantities, methods are means that laboratories must use a method with an ap-
calibrated by serum matrix- calibrators and often by se- propriate calibrator and measured on specific measure-
rum (multi)calibrators which are not included within the ment equipment, in accordance with standard operating
kit components. Consequently, traceability to trueness of procedures. If this principle is not respected, there are no
a kit will depend on traceability of the calibrators used, stable performance conditions and the set-up of adequate
Therefore, it is important that manufacturers recommend control procedures is impossible.
appropriate calibrators for each kit. Immunoassay kits Many dinical laboratories are stm not convinced that,
normally include calibrators within each reagent pack- eyen when they dQ nQt ^  a so_called closed method)
age, hence the problem of the choice of recommended ±  sh(juld ^  ^  QWn dosed gygtem (calibrator)
calibrators is irrelevant for most of these assay kits. kit, measurement equipment). Even if the performance
Clinical strategies
For those quantities where reference method values are conditions are stable, traceability to trueness can only be 
available, traceability to trueness for calibrators and con- obtained if the manufacturer is more aware of traceabil- 
trol sera should be performed, preferably by split-sample ity to trueness rather than to comparability of his results 
measurement with accuracy-based reference methods with those obtained with the kit/testsystem of a market 
and routine method measurements on a representative leader for the same quantity. In this case, the method 
panel of patient specimens (12). In this way, target set- should be calibrated with the recommended calibrator(s)
by the manufacturer. If this concept is not respected, all 
efforts from industry for traceability to trueness are 
worthless.
The concept of homogeneous methods must be pro­
moted by EQA organizers by giving global results for 
the homogeneous method groups with sufficient users. 
Using EQA results, Devleeschouwer et aL (17) could 
demonstrate that traceability of C-reactive protein results 
for the same kit was much better for the users of the 
calibrator recommended by the manufacturer, as com­
pared to the group using calibrators from other origins.
According to the expansions described above and fo­
cused on EQA, the model from figure 1 can be extended 
for the analytical quality creation element as illustrated 
in figure 3:
Specifications 
for imprecision Expert opinions.
Reference values
State of the art
Others
Analytical quality 
specifications
Analytical quality Externa! quality
creation assessment
Fig. 2 Extended model for analytical quality specifications
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model for the analytical quality control is visualized in 
figure 4. The different EQA systems (proficiency test­
ing, traditional and educational EQA) will be described 
further in this paper.
Recommendations for specifications of control materi­
als, used in EQA schemes, have been prepared by Work­
ing Group C (18). Appropriate statistical evaluation pro­
cedures (which can be considered as belonging to the 
scheme design) and' design of reports are under discus­
sion in Working Group D.
Design of 
IOC system
Fig. 3 Model for analytical quality, including the extensions for 
EQA.
Analytical quality 
specifications
Internal quality 
control PQC)
Analy t i ca l  q u a l i t y  con t ro l
In contrast to the generally accepted idea, analytical 
quality control cannot by itself improve the quality of 
an analytical process. Quality control by itself cannot 
create the desired quality, but primarily monitors it. 
Quality control processes can disclose or reject errors at 
best but the revelation of errors may be the first step in 
a trouble-shooting process which may lead to correction 
of the error, and thereby, to improvement in the analyti­
cal quality. It is important to distinguish between the
Analytical Analytical 1
quality creation quality control |
Materials 
for IQC
Design of 
EQA system
(External quality control (EQA)
Materials 
for EQA
Fig. 4 The model for analytical quality from figure 1, illustrating 
the expansion of analytical quality control elements.
Objectives of EQA schemes
Participant
performance
Check of performance
External
quality
assessment
Method
performance
possibilities for error detection by internal quality con- Based on the concept described above of quality manage- 
trol and external quality assessment systems. EQA is no ment with analytical quality specifications, analytical 
substitute for internal quality control, but complements quality creation and quality control, we can develop a sim- 
it. The external system should disclose errors in the indi- ilar model, describing the main elements of EQA (fig. 5). 
vidual laboratory’s stable performance, i. e. the chosen 
method with its calibration and implementation, whereas
the internal control should disclose deviations from Objectives
stable performance. Therefore, the external system is 
mainly a documentation of the stable situation and if the 
quality is unacceptable, then the method or the calibra­
tion should be changed. The external system thus deals 
with the stable analytical bias, but in some quality as­
sessment schemes it also deals with documentation of 
random errors in order to assist the laboratories in their 
internal system. The fundamental strength of EQA is the 
large amount of data created, allowing conclusions to be 
drawn on sound statistical bases. The checking is neces­
sarily retrospective and the comparison of a given labo- 5 M°del f°r quality achievement applied to EQA.
ratory’s performance on a certain day with that of other
laboratories cannot be notified to the laboratory until In each EQA scheme* we catl distinguish the following
some time later. This comparison will therefore have no ^ree basic elements,
influence on the laboratory output on the day of the chal- (0 quality specifications (objectives),
lenge. The objective of EQA is not to bring about day- (ii) tools and
to-day consistency but to give insight into between-labo- (iii) follow-up. 
ratory comparability.
Tools
Appropriate sample(s) 
Scheme design 
Appropriate evaluation
Follow-up
Communication with 
participants
The
determine
1
The quality of an EQA scheme is obtained by linking 
these elements together. The objectives of EQA are of 
two types:
since control materials as well as interpretation of the (i) participant performance evaluation and 
results are decisive for the outcome. The extended (ii) method performance evaluation.
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Creation of quality is defined by the tools. These tools out a proficiency certificate may become ineligible to
are: appropriate samples, scheme design and an appro- receive reimbursement from government or health insur-
priate evaluation procedure in accordance with the ob- ance agencies for the investigations they perform, Pro-
jectives. Without defining the objectives, it is not pos- fessional sanctions may be applied by, for example, sci-
sible to elaborate the tools and to inform the participants entific societies or academies, in refusing to accord the
about the performances of the methods used and about status of recognised training centres to laboratories that
the implementation. We can describe this concept as do not participate in such schemes or show poor perfor-
“problem related quality control” . 
Pa r t i c ipan t  pe r fo rm an c e  eva lua t ion
mance in them (2 1 ).
According to Aronsson et al. (22), international and re­
gional EOA schemes can be used to assess one or more 
Participant performance evaluation is related to the im- of the following aspects from the analytical objectives:
plementation of a method in a laboratory. The discussion 
within this paper is limited to the analytical aspects of 
the participant assessment. Other aspects of participant
(i) the quality of the analytical performance of the indi­
vidual participants laboratory;
assessment such as: personnel, laboratory infrastructure, (ii) the state of the art performance of the participating 
internal quality control, etc., are beyond the scope of laboratories;
this publication.
The primary aim of this evaluation is to assess the analyti­
cal quality of the individual laboratory in relation to other
(iii) intra-laboratory variation;
(iv) inter-laboratory variation;
laboratories using the same methods and if possible, sub- (v) relationships between calibration procedures and an-
mitted to exactly the same external sources of quality. alytical results;
Participant performance evaluation can be approached (vi) relationships between analytical procedure (proper) 
from two aspects; when is a result acceptable from a and analytical results;
medical point of view (health policy objectives) or when 
is a result acceptable from a purely analytical viewpoint 
(analytical objectives)? As health policy objectives are
(vii) relationships between commercial reagents and 
analytical results;
also based on analytical performances in the long run, (vüî) relationships between analytical instruments and
this theoretical split is not so clear in practice. Indeed, analytical results;
the performance evaluation will be based in both cases (ix) state of the art values for concentrations of the con-
on analytical acceptable criteria, which can be different stitUents of the circulated material; and
from each point of view.
(x) systematic deviations for the individual laboratory
The health policy objective of EQA is betterment of fVOm state of the art values or values obtained by applying 
health care through improvement in laboratory perfor- reference or definitive methods to the circulated material.
mance. A national EQA programme can bring about 
such an improvement in two ways:
(0 by providing education, training and help for 
laboratories which require these or
(ii) by recognising laboratories with unsatisfactory per- ^  Wotkjng Group suggestg that the concepts ofAm ns_ 
formance (19, 20) and imposing sanctions on laborato- ^  et al (22) ghould be expandcd t0 include analyticai 
ries with persistent failures, thus effectively preventing qualjty specifications for participant and method perfor-
Some of these points overlap, but each represents a spe­
cific question put forward in connection with EQA. Ef­
forts should be made to obtain information about most 
of the ten points in every EQA.
mance evaluation.them from contributing to the service.
Most European countries favour the first approach and
most national EQA schemes put stress on education and Method  p e r f o r m a n c e  e v a l u a t i o n
training. Participation in such programmes can be man­
datory or voluntary. Some countries, in addition, insist 
on bringing about a general improvement of laboratory
»
standards by means of legal, financial or professional 
sanctions applied to laboratories which show poor per-
A method includes reagents, a calibrator and well de­
fined measurement equipment. It is impossible to evalu­
ate the reagents without considering the two other ele­
ments .
formance. Legal sanctions may be applied to the denial Method performance evaluation encompasses several as-
of certificates of proficiency to the laboratories that are pects, such as: traceability, specificity, linearity, limit of
unable to reach defined standards of performance, and detection, interferences, precision, etc. In fact, all these
this in effect prevents them from practising. Financial factors influence the quality of the result o f a measure -
sanctions may be similarly imposed: laboratories with- ment. All analytical aspects of a method evaluation
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should be investigated internally and comprehensively 
by the developer of the method before release on the 
market (see creation of quality). In this validation, trace- 
ability of calibrators is very important. Traceability is a 
task for industry, preferably supported by a network of 
reference laboratories. However, only few manufacturers 
are currently convinced that results obtained with their 
systems should be traceable to values based on recog­
nised reference methods established either on the basis 
of split-sample patient samples or with the help of in­
ternational reference preparations.
For the evaluation of method performances, a method 
independent target value, as far as possible traceable to 
trueness, is necessary,
EQA does not compete with the pre-market validation, 
but monitors the field performances and the ways in 
which methods are implemented in routine laboratories. 
It must also be mentioned that method assessment in 
EQA has not the same goal as the method assessment 
evaluation during the pre-market phase. In EQA, perfor­
mance evaluation is often linked to the routine use of a 
method on well defined measurement equipment and a 
calibration system, which can be different from the rea- 
gent-calibrator-instrument combination used by the 
manufacturer during his validation process. Only EQA 
organizers have the information about which combina­
tions of reagent-calibrator-instruments are used and 
must create homogeneous groups of users from the same 
method. For those groups with a sufficient number of 
users (same kit, same calibrator, same measurement 
equipment), an educational EQA scheme will evaluate 
the performance of these methods and the performances 
of each participant by comparing their results with those 
of other users of the same method. The importance of 
EQA as a post-market evaluation tool for industrially 
prepared kits and reagents is recognized in the European 
draft directive on in vitro diagnostics ( 1 1 ).
Cr i t i ca l  e v a l u a t i o n  o f  EQA sys tems
Under the general umbrella of the EQA system, we 
can distinguish:
(i) proficiency testing,
(ii) “traditional” EQA schemes and
(iii) “educational” EQA schemes.
The requirements on control materials and on evaluation 
procedures are similar for all the different types of EQA 
schemes; only scheme design and criteria for acceptable 
performance may vary.
P r o f i c i e n c y  t e s t i ng
Sanctions linked to inadequate performance are a dis­
tinctive characteristic of proficiency testing.
Successful participation for laboratory accreditation is 
required by several US Institutions such as the Health
Care Financing Administration (HCFA regulations), 
Medicare, Medicaid, the Joint Commission on the Ac­
creditation of Healthcare Organisations (JCAHO) and 
the College of American Pathologists (CAP).
To pass proficiency testing, clinical laboratories must 
meet desirable standards laid down under the Clinical 
Laboratory Improvement Act (32).
In Western Europe, the only EQA system classified as a 
proficiency testing programme exists in Germany and is 
conducted under legal constraintments laid down in the 
“Richtlinien der Bundesárztekammer” (RILIBÁK) (24), 
The merits of the German system are especially influ­
enced by the fact that, in the original concept developed 
by Stamm (25), acceptability limits were based on refer­
ence values. This scheme uses reference method values 
as target values when reference methods are available 
(electrolytes, metabolites and substrates, steroid hor­
mones, thyroxine and some therapeutic drugs). This is 
an unusual situation because the use of a single target is 
not the most appropriate for participant assessment. For 
all other quantities, where no reference methods or stan­
dardized methods are available, different method-depen­
dent target values are used to evaluate the performance 
of participating laboratories.
Because of the possible sanctions, proficiency testing 
schemes have to respect current analytical performance 
and, hence, are often restricted in the limits they choose 
and the nature of targets they apply. For example, the 
German EQA limits for some steroid hormones had to 
be widened when method dependent target values were 
substituted with reference method target values (26) be­
cause, currently, calibration and/or specificity of test-kits 
from different manufacturers is not compatible.
Because of the possible sanctions, proficiency testing 
schemes have to take extreme care that laboratory per­
formance is not confounded by method performance (9). 
As an example, it is impossible in a proficiency testing 
scheme to include samples that contain interferents in 
order to assess method specificity (27, 28). In a pure 
proficiency testing scheme, participant assessment must 
be independent from the measurement procedure used, 
because a user cannot be blamed for shortcomings of 
the method itself (he can only be blamed for using a 
method with poor performances). Therefore, CAP uses a 
protocol to compensate for the bias of the measurements 
procedure, based on the simultaneous determination of 
fresh human sera and CAP survey specimens (29).
It could be presumed that the basic quality specifications 
should be the same for regulatory (licensing, accredita­
tion) purposes in different countries. However, large dif­
ferences are observed in the applied acceptability limits. 
For the same results for the same quality, the laboratory 
would fail proficiency testing in one country but would 
pass in another and vice-versa (30).
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The rationale behind the different limits is not always 
clear and is based on different quality specifications. Fi­
nally, proficiency testing schemes might not mirror true 
laboratory performance because of tendencies to use 
special practices for EQA samples (31) in order to pass 
a survey. In fact, a participant cannot afford the smallest 
risk of loosing their certification (license),
In conclusion, it can be stated that pure proficicncy test­
ing schemes have recognized major limitations. In spite 
of the intentions of protecting against unprofessional 
performance, proficiency testing has a tendency to main­
tain the quality at a certain level and is unable to stimu­
late improvement of quality above this level.
Traditional EQA schemes
A review of European EQA schemes was published by 
Measurement & Testing from the EU (32). Moreover, 
other authors have extensively reviewed EQA schemes 
in all the disciplines of clinical pathology (4, 33—35). 
In most European countries, EQA schemes belong to the 
category of traditional schemes.
EQA will only reflect routine quality if all users are 
allowed to treat the EQA samples in the same way as 
usual patient samples, even with the risk of making a 
mistake. Since no sanctions are linked to poor EQA re­
sults, there is a greater chance that a traditional EQA 
(with essential educational purposes) will give a more 
realistic reflection of the routine quality of a laboratory 
than proficiency testing schemes. In contrast to profi­
ciency testing, more stringent acceptability limits can be 
used in EQA.
The VALTECH (“Commision: validation des tech­
niques) criteria (36) in France and the Combi-scheme in 
The Netherlands (37), for instance, both based on bio­
logical variation, are used for drawing the attention of 
laboratories to their current quality and for promoting 
higher quality methods. In constrast to proficiency test­
ing, EQA schemes can introduce experimental samples 
for which it is known that a majority of the participants 
will fail, but with an important educational impact and 
particularly when the results are discussed in detail in 
the comments on the survey. Such surveys cannot be 
organized in proficiency testing.
In some countries, such as Belgium, Luxembourg, France 
and several Eastern Europe countries, participation in 
EQA schemes is mandatory. These schemes remain edu­
cational and cannot be linkened to proficiency testing 
schemes as there are no sanctions directly coupled to labo­
ratory performances in EQA. Mandatory participation, as 
foreseen in the countries mentioned, will force these 
laboratories to participate, which would not be the case in 
a completely free system. Therefore, participation in the 
official EQA schemes is included in the licence condi­
tions in Belgium and France; in these countries EQA is 
organized by governmental organisations.
In a majority of the countries, participation in EQA 
schemes is completely voluntary and national or re­
gional EQA schemes are organized by professional or 
scientific societies and by non-profit organisations.
In addition to “official” EQA schemes, it must be men­
tioned here that there are several commercial EQA 
schemes often coupled to the purchase of control materi­
als. These schemes are often linked to a well-defined 
group of users of the same method.
Acceptable performance criteria in European EQA 
schemes were reviewed in another paper by our Working 
Group (38) and by Libeer (4),
Traditional EQA schemes normally send out two sam­
ples per survey. Participants are asked to perform a sin­
gle determination on each sample. Results are usually 
grouped according to method groups. Since a result is 
not only influenced by the analytical principle, but also 
by the reagent, calibrator and measurement equipment, 
it is sometimes extremely difficult to create homogen­
eous participant groups with a representative number of 
participants. Most traditional EQA schemes do not have 
all of this information at the moment.
As a consequence of the single determination, it is diffi­
cult to assess laboratory performance in terms of bias 
and random errors.
Several traditional EQA schemes give a review of the 
group performances for each sample. In clinical chemis­
try however, many incorrect conclusions might be drawn 
from such evaluations, because all the groups do not 
cover the same contents: some groups cover only the 
same analytical principle (e. g. glucose hexokinase 
methods, covering different kits and instruments); other 
groups cover a well-defined method (e.g. glucose re- 
fleetometry, covering only Johnson & Johnson slides 
on Ektachem).
Educational EQA schemes
In Europe, an increased awareness of the deficiencies 
and the shortcomings of the design of most current 
“traditional” EQA schemes is growing. Some of these 
criticisms were already mentioned under proficiency 
testing and traditional EQA. Educational EQA tries to 
improve traditional EQA (and the inherent shortcom­
ings) and to add a new scope, emphasizing quality im­
provement.
As a consequence of this new approach, the following 
elements are to be considered:
(i) assessment of the overall analytical quality, includ­
ing long-term follow-up
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(ii) conducting specialized EQA schemes, where spe­
cific analytical pitfalls are studied
(iii) assessment of quality improvement
Control specimens distributed in EQA schemes must be 
carefully designed to provide correct information and be 
appropriate for the intended objective (40).
For example, single target setting is inappropriate for
(iv) supporting internal quality control continuously by partjcipant assessment, while multiple target setting is
specially designed EQA schemes inappropriate for method assessment (9) and jeopar-
(v) monitoring the methods and the laboratory perfor- dizes efforts for method harmonisation (20). Bias as- 
mance through a simplified EQA scheme using detailed sessment of methods needs native sera, while pro­
information about methods cessed, lyophilized materials are mostly inappropriate
, x. i . » , ^  , , for that purpose because of “matrix effects” leading(vi) stimulating proper action taken by the laboratory ................ . . //11X ^
,'  , . rr to non-commutabihty with patient specimens (41). Ex- when deviating findings occur  ^ i . \  i-.
amples of EQA designs according to analytical quality
(vii) promoting of the use of common reference in- specifications, given in the appendix, demonstrate how 
tervals where relevant and the use of modern nomencla- traditional EQA schemes could evolute to educational 
ture. and units in collaboration with other interested pro- E q A  schemes by a problem related approach for the
fessionals or societies. organisation of the schemes, according to objectives
As observed, the scope of an educational EQA scheme set a priori.
is much larger than traditional schemes and quality as- jn order to schematize these various possibilities, the
surance elements are also included. Working Group first classified the analytical factors,
We could define educational EQA or external quality which are principally factois involved in analytical qual-
assurance as problem related external quality assess- ity* ma(te a main distinction between external
ment, allowing the participants to define the origin of factors (factors associated with the method assessment)
problems for aberrant results and to find the appropriate anc  ^ internal factors (factors associated with the labo-
remediation procedure. Therefore, analysis of the data ratorY implementation) and between permanent and
returned to laboratories by the organizers of EQA variable factors (see tab. 1).
schemes must be improved so that poor performance
can be properly highlighted, the reasons for the poor
performance made readily apparent to all involved in analyt ica l  qual i ty
laboratory medicine, and educational advice for trouble- A schematic presentation of the relevant factors in-
Class i f i ca t ion  of  re levant  factors  involved  in
shooting provided if  required (39). volved in analytical quality is given in table 1 .
The Working Group stresses that the design of an educa- The permanent external factors are related to the labora-
tional EQA scheme should always bear in mind which tory’s choice of the analytical principle, the equipment,
objective it desires to address. The EQA design should the calibrator and kit-reagents, etc. This can only be
reflect this before sending out the samples, rather than modified by selecting another (better) analytical system,
try to extract the data afterwards, for example, bias data The individual laboratory has little influence on the
from a survey that primarily was intended for investiga- quality of these products. The impact of these factors on
tion of method CV. This approach will affect selection EQA will result in
of the sample type (e. g. native or processed and lyophi- (i) deviating values (from a true value) for all laborato-
lized), the number of measurements to be performed by t •+ At \. . . nes using the same method or kit and (or)
the individual laboratory (single or multiple), the type of
target (group-mean, consensus, reference method), data inferioi imprecision performance (elevated
grouping (built-up of homogeneous groups with respect method group CV).
to method, manufacturer of reagents, instrument, etc.), In the first case, the producer has to review the choice
number of surveys conducted per year. of basis for calibration and for the traceability back to
Tab. 1 Factors involved in analytical quality
Sources External factors Internal factors
Permanent factors Analytical principle, Method, Implementation in the Laboratofy s choice o f  quality
Equipment laboratory, Instructions
Variable factors Variation in batches Variation in performance and Expected and unexpected variation
regular errors
Manufacturer s responsibitity Laboratory's responsibility
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this (situation where EQA samples were proved to be 
commutable); in the second case the method is to be 
considered as poor because of the inherently poor meth­
odological principle or because the implementation of 
the analytical principle as it is worked out in the method 
or in the measurement equipment is bad. These systems 
should be abandoned
The Working Group considers that the permanent exter­
nal factors do not need to be assessed more than once
>
a year, but carefully investigated and measured during 
several days.
The permanent internal factors are related to the imple­
mentation of the method in the laboratory (reagent/sam­
ple volumes, commercial calibrators, the number of cali­
bration points, curve fittings, calculation factors, time 
factors, etc.)* As an example, albumin determination 
with bromocresol green is usually treated by a linear 
function, although a logarithmic function is more appro­
priate. Further, the time factors chosen may result in dif­
ferent sensitivity for non-specific reactions, e. g. in the 
Jaffe creatinine determination. The influence of aceto- 
acetate on the Jaffe creatinine determination can be 
neglected if incubation time before the first reading is at 
least 60 seconds (28). These problems are highlighted in 
EQA by systematic deviation from the method group 
mean (median) for individual laboratories within the 
same user group.
Permanent internal factors must be controlled during 
verification of the implementation of the method in the 
laboratory and in practice also once a year, so that the 
current ‘permanent1 situation is kept up to-date.
For this control, materials with known values are 
needed. These materials should be available to the users 
by the manufacturers, when new methods are introduced 
or when difficulties arise. These materials could also be 
included in EQA and made available by EQA organiza­
tions.
The variable external factors are due to variations in 
batch production (both calibrators and reagents). This 
can best be controlled when new batches are compared 
to old batches by selected laboratories, before they are 
released for all laboratories, and by the individual labo­
ratory when using a new batch. Another course of action 
would be to obtain from the producers a better warranty 
for closer batch to batch variations and to advise 
laboratories to use the same reagent and calibrator 
batches over a long period.
As EQA surveys are organized in fixed schedules, it is 
practically impossible to control these factors in an 
EQA. On the contrary, laboratories should be aware of 
this problem and increase internal control procedures 
when batches are changed.
The variable internal factors must be controlled
(i) by the laboratory internal quality control system in 
each run and
(ii) in the external quality assessment by evaluation of 
random deviations from the method group mean (me­
dian) for individual laboratories.
For an evaluation of variable internal factors, it will be 
necessary that participants perform multiple measure­
ments in several series.
In table 2, the most relevant characteristics of each of 
the described factors responsible for analytical quality 
are mentioned.
Essen t i a l  t asks  o f  e d u c a t i o n a l  EQA schemes
Existing EQA schemes include less or more elements of 
educational EQA schemes and in practice there is not 
such a clear distinction between the two. In a traditional 
EQA approach, a survey is run and afterwards the orga­
nizer tries to draw conclusions. Educational EQA 
schemes are more structured from the beginning: the ob­
jectives are well defined and the concept planned be­
forehand. Within educational EQA schemes, we distin­
guish the following essential tasks:
(i) Monitoring and
(ii) evaluation of relevant quality factors.
Monitoring
Monitoring does not evaluate individual EQA results of 
participants; only pure assessment is considered here 
without any reference to quality specifications, As an 
example we can mention the state of the art performance 
of a participant group, long-term follow up of this per­
formance, comparison of the performance from one par­
ticipant group (country) with another, performance com­
parison of different analytical principles.
This information is important for the demonstration of 
the quality of clinical laboratories in general,
« i
Tab. 2 Most relevant characteristics of factors involved in analyt­
ical quality
Permanent Traceability Calibration function
factors Linearity Systematic error
Interference Carry-over
Specificity Contamination
Detection limit Conformance to
Precision profile consensus value
Instrument variability 
Commutability of 
control materials 
Carry-over
Utensils
Variable Batch variability Within-run imprecision
factors Stability o f reagents, Within-day imprecision
calibrators Between-run imprecision 
Between-day imprecision 
Long term performance
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Evaluation o f quality factors
Knowledge of the relevant factors involved in analytical 
quality allows the design of educational EQA schemes 
to be focused on the problems one by one.
fied fresh native sera in several concentration ranges. A 
preliminary selection of participants allows the needed 
information to be gathered in a much more economical 
way. This approach does not mean that the information 
must only be available to the participating laboratories,
EQA can be used for the investigation of all factors in- but it is also important that the evaluation report should 
volved in analytical quality as resumed in table 2. How- be communicated to all the scheme members.
ever, EQA is not always the most appropriate tool to be 
used for every item to be investigated.
By using dedicated designs and samples, EQA can be 
used for studying robustness of methods, sensitivity to
Table 3 gives a review of which factors should best be interferences, linearity, recovery, specificity and other 
investigated by internal quality control procedures and permanent factors. Several examples of such studies can 
those which are appropriate for EQA schemes. Exami- be found in the UK steroid hormones NEQAS (43).
nation of the factors involved in analytical quality al­
lows the definition of the essential tasks for educational 
EQA schemes.
For these evaluations, if only a limited number of parti­
cipants are asked to collaborate, a practical problem 
arises: in most countries laboratories have to pay a fee 
Examples of problem oriented designs of educational for their participation in the EQA programmes. Some
EQA schemes are given in the appendix. participants could argue that they do not want to pay for
Within the evaluation of permanent external factors, the Performance evaluation of a method, but only for
traceability is one of the most important. their own performance evaluation. To avoid this situa­
tion, each survey concept on method performance eval-
If the concept of a network of independent reference uation should also try to give maximum information on
laboratories is widely accepted by the manufacturers and the performances of the individual participant.
if all results on traceability of methods are available for
jjr .. ■ i n it *j * ___ i Batch variability of reagents and calibrators can best beEQA organizers and for the users, then it is supposed it 4 t 6 f , 1
that this type of verification should be done only once a
year. EQA has a major task to demonstrate bias of meth- of rea®ents or calibrators’ laboratories should increase
ods and, together with the users, to stimulate manufac- t*ie’r Inteina  ^ control piocedures.
turers to provide more accurate methods. If a sufficient number of users of the same batches are
When
-p ,i - . . jv» * , ,» , t found, in EQA it is possible to compare the perfor-For this assessment, it is sufficient that only a represen- ^7:« , , ,.
i r  + n i mances of different batchnumbers for calibrators andtative number of participants from a homogeneous group
methods.
The requirements for appropriate control sera for 
method performance evaluation are high, namely certi-
assay the samples. Indeed, it would be a waste of re­
sources to try to generate homogeneous groups after This assessment aims at the verification of the correct 
performing a survey. This approach presumes that the implementation of a method within the laboratory (in- 
EQA organizer has knowledge, not only from the analyt- eluding calibration function and the setting up and work- 
ical principle groups to which the participants belong, ing out of the performance). Correct implementation 
but also from the reagent, calibrator and measurement will result in an acceptable laboratory component of 
equipment in use from each participant, A practical ex- bias. The impact of the laboratory component of bias 
ample of such a survey is published by Stock! et al. (42). can only be evaluated if the bias of the measurement
procedure elements (belonging to the external perma­
nent factors) are eliminated. The laboratory component 
of bias is defined as the difference between the group 
mean value of the users of a same method and the inter­
run laboratory mean (7).
According to the problem related control approach, edu­
cational EQA must give an answer to the participant if 
performance is sufficient to meet to the assumed quality 
specifications. If this is not the case, maximum informa­
tion must be given in order to disclose the problems.
In a previous paper on desirable analytical performance 
standards (8), the Working Group recommended that 
quality specifications should be based on biology. These 
desirable analytical performance standards must then be 
specified in terms of maximum allowable bias and im­
precision for monitoring and for diagnostic testing.
Tab. 3 Essential quality functions for IQC and EQA related to 
the factors involved in analytical quality
Sources Externa] factors Internal factors
4
Permanent
performance
External quality 
assessment
External quality 
assessment
Variable
performance
Internal quality 
control
(External quality 
assessment)
*
Internal quality 
control
Kit/test system 
performance
Participant
performance
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When achieved, these performance standards should 
guarantee optimum patient care.
Often a participant is not able to improve the inherent 
bias of the analytical principle and the traceability of 
the method used. The laboratory component of bias 
can be evaluated by comparing the mean of multiple 
determinations (grand mean) from one laboratory ver­
sus a consensus value (mean or median). The differ­
ence between the consensus value and the reference 
method value cannot be considered as an estimation 
of the bias of the measurement procedure if commuta- 
bility of the control samples has not been investigated. 
A method for commutability evaluation of control sera 
was described by Malavasi et al. (44) and Baadenhuij- 
sen et al. (45).
Maximum allowable bias and imprecision for meeting 
the assumed quality specifications can be evaluated 
separately or by combining the different components: 
bias of the measurement procedure, laboratory compo­
nent of bias and random errors.
For cholesterol, the national cholesterol education pro­
gramme (NCEP) Laboratory Standardisation Panel (46) 
goal guidelines state that inaccuracy is acceptable if the 
bias is <  ±  3% and CV ^  3%. If for other quantities, 
the goal shares common reference intervals, then the ac­
ceptable performance will take into account both as­
pects. The examples for cholesterol and for plasma pro­
teins are shown in figure 6 .
Since the acceptable bias is a combination of the labora­
tory component of bias and bias of the measurement pro-
r
Laboratory 1
Imprecision (CV [%])
1
o
1 Laboratory 2
-3 -2 -3 0 +1 +2 +3 Bias [%]
14 _ 
12
10_
L  8Cfi.5 6 0Û
2 -
0
Allowable combined 
bias and imprecision for 
specific plasma proteins
Haptoglobin 
IgA 
. igM
f a,-Acid glycoprotein
I igG
[
Transthyretin (Prealbumin) 
a,-Proteinasa inhibitor 
Transferrin 
Albumin
T
10 15 20 
CV [% ]
30
Fig. 6 Acceptability limits for bias and imprecision, 
a: is the example for cholesterol where bias and imprecision are 
considered independently: Lab 1 conforms to both specifications, 
Lab 2 conforms to the specifications for imprecision but the bias 
is too large.
b: is an example o f the combined bias and imprecision as used 
in the Nordkem protein project for specific plasma proteins (49) 
(reproduced with permission).
Support of internal quality control. According to
cedure, the maximum allowable laboratory component of ^  degign of tfae schemes> participants are asked t0 
bias will depend on the bias already taken up by the manu­
facturer for the method itself. A discussion about the max­
imum allowable bias of the measurement procedure for 
each quantity between all involved parties (industry, EQA 
organizers, professionals) would be useful.
perform one or several measurements. Multiple mea­
surements can be used for the evaluation of labora-
Quality assurance tasks
tory imprecision,
— To provide educational assistance and education. The 
laboratory Proficiency Testing Program in Toronto (Can­
ada) even has a teleconference programme for inter-
The educational role of EQA schemes is very important. a°tive education (48).
Quality of a laboratory result does not stop with a cor­
rect analytical result. Also, EQA can be helpful in data 
interpretation by collecting other information from parti­
cipants and by appropriate evaluation of these data. Ex- Table 4 lists problem related EQA designs for method
Appendix
amples include:
-  EQA schemes can ask that protein results are cal­
ibrated against the new worldwide available CRM 470
evaluation with their essential prerequisites. Practical 
examples for participant evaluation and for method 
evaluation are elaborated further in the following ex-
so that results between laboratories are more coherent. amP^ es-
Appropriateness of reference intervals used. Exam- L E x a m p l e s  of  EQA s c h e m e s  for  p a r t i c i p a n t
pies are found in the Danish EQA scheme for specific 
proteins (47).
— Correct interpretation 
immunoassay scheme has 
this field.
p e r f o r m a n c e  e v a l u a t i o n  
Frequency:
of results. The Murex 
considerable success in 3 - 1 2  times/year, according to the needs and the practi­
cability within the EQA scheme.
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Tab. 4 Problem oriented designs: examples o f essential prerequisites
Investigation Sample nature Target setting
Measurement procedures bias Native human serum Reference method value
Laboratory component o f bias Native human serum Method group mean and reference method 
value
Within-method CV (between laboratories) Any stable material No target value
Method specificity and interferences Two identical sera with/without added No target value
substances V
Laboratory systematic deviation Any stable material Method group mean
Needed information:
Reagents (Manufacturer, analytical principle, possibly 
batchnumber).
Calibrators (manufacturer, type, possibly batchnumber). 
Measurement instrument (manufacturer, type).
Prerequisites:
Processed samples.
Target being the mean (median) of a homogeneous 
group (same analytical principle, same reagent, same 
reagent with same calibrator(s), same reagent with same 
calibrator(s) on the same type o f measurement instru­
ment, etc.).
Statistically sufficient number of participants of a homo­
geneous group.
Statistically sufficient number o f measurements per­
formed under stated conditions,
EQA scheme design 1:
2 samples/event and 1 measurement/sample (giving two 
data points/participant).
Conclusions to be drawn:
Basic information on the use of different methods, al­
lowing identification of the users of a homogeneous 
group.
Estimation of the state of the art performance based on 
the overall method mean (median) and in the method 
groups with sufficient users.
The deviation of the individual result from the group 
target is composed of imprecision and bias components.
No estimation of the laboratory component of bias.
No estimation of the intra-laboratory reproducibility.
No estimation of the bias of the method,
EQA scheme design 2:
2 samples/event and 6 measurements/sample: duplicates 
on 3 days (giving 12 data points/participant).
Conclusions to be drawn:
Basic information on the use of different methods, allow­
ing identification of the users of a homogeneous group.
Estimation of the state of the art performance based on 
the overall method mean (median) and in the method 
groups with sufficient users.
Estimation of the laboratory component of bias in these 
homogeneous groups with sufficient users.
Estimation of the intra-laboratory reproducibility.
No estimation of the method bias (even if a reference 
method value is available, the method bias can be erro­
neous due to possible lack of material commutability).
Design 2 gives better estiination of deviation and allows 
calculation of reproducibility, but creates more data to 
process and imposes a higher workload on a participant,
2. Examples  of  EQA schemes for  method  p e r ­
formance  eva lua t ion
Frequency:
Once a year, or after the introduction of new kits or 
methods with sufficient number of participants.
Needed information:
Reagents (manufacturer, analytical principle, possibly 
batchnumber).
Calibrators (manufacturer, type, possibly batchnumber). 
Measurement instrument (manufacturer, type).
Prerequisites:
Native serum samples.
t *
Target being a conventional true value (ID-GC/MS ref-
«
erence method value).
Statistically sufficient number of participants of a homo­
geneous group.
Statistically sufficient number of measurements per­
formed under stated conditions.
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EQA scheme design 1:
Four frozen native serum samples, “single donations”.
Homogeneous group of 20 laboratories; 6 measure­
ments/sample: duplicates on 3 days (giving 120 data 
points/sample).
Conclusions to be drawn;
n 9
Estimation of the method bias.
Estimation of the inherent reproducibility of the method. 
Estimation of the laboratory component of bias 
Estimation of the intra-laboratory reproducibility
EQA scheme design 2:
Four frozen native serum samples, “single donations”.
Homogeneous group of 40 laboratories; 1 measure­
ments/sample: (giving 40 data points/sample).
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